Analyst Expectations for Kezar Life Sciences's Future
Portfolio Pulse from Benzinga Insights
Kezar Life Sciences (NASDAQ:KZR) has received positive ratings from analysts, with 3 bullish and 1 indifferent rating in the last quarter. The average 12-month price target for KZR is $15.5, with a high of $20.00 and a low of $2.00. This target has increased by 40.91% over the past month, indicating a positive outlook from analysts on the stock.
November 27, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kezar Life Sciences has received predominantly bullish ratings from analysts, with an average 12-month price target of $15.5, which has seen a significant increase of 40.91% in the past month.
The positive analyst ratings and the substantial increase in the average price target for KZR suggest a strong bullish sentiment, which is likely to have a favorable impact on the stock price in the short term. The unanimous bullish and indifferent ratings without any bearish outlooks reinforce the positive sentiment. The significant increase in the price target over the past month further underscores the analysts' confidence in the stock's potential.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100